Multiple Sclerosis: An Abiotrophy with Heuristic Implications

  • E. J. Field
Part of the Ettore Majorana International Science Series book series (EMISS, volume 16)


These words remain as cogent today as when penned; neither is it widely appreciated that 0.5–1.0% of all MS patients are first referred to a psychiatrist (personal communication from Dr. L.H. Field). The existence of totally “silent” cases of MS is now well established (Georgi, 1961; Vost et al., 1864; Ghatek et al., 1974; Morariu and Klutzow, 1976; Castaigne et al., 1981). Georgi’s series is biggest and best known. He found amongst 15,644 autopsies carried out at Basle Institute of Pathological Anatomy, 68 cases of anatomically demonstrable MS, in 12 of which (18%) the disease had not been at all suspected during life. Mackay and Hirano (1967) were of the considered option that “perhaps clinically silent multiple sclerosis occurs in about one case for each four definitely diagnosed clinically”.


MUltiple Sclerosis Arachidonic Acid Unsaturated Fatty Acid MUltiple Sclerosis Patient Experimental Allergic Encephalomyelitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Allen, I.V., 1983, Hydrolytic Enzymes in MS, in: “Progress in Neuropathology”, Vol. 5, H.M. Zimmerman, ed., Raven Press, New York, 1–17.Google Scholar
  2. Allen, I.V., Glover, G., and Anderson, R., 1981, Abnormalities in the microscopically normal white matter in cases of mild or spinal Multiple Sclerosis (MS)., Acta Neuropath.(Biol)., Suppl. IV: 176–178.CrossRefGoogle Scholar
  3. Anton, G., and Wohwill, F., 1912, Multiple nicht eitrige Encephalomyelitis und Multiple Sklerose., Z.ges.Neurol.Psychiat., 12: 31–98.CrossRefGoogle Scholar
  4. Arstila, A. U., Riekkinen, P., Rinne, U. K., and Laitinen, L., 1973, Studies on the pathogenesis of multiple sclerosis: Participation of lysosomes on demyelination in the central nervous system while matter outside plaques., Eur.Neurol., 9: 1–20.CrossRefGoogle Scholar
  5. Berry, R. J., 1969, Genetical factors in the aetiology of Multiple Sclerosis, Acta Neurol.Scand., 45: 459–483.CrossRefGoogle Scholar
  6. Bisaccia, G., Caputo, D., and Zibetti, A., 1977, E-UFA test in Multiple Sclerosis, Boll.Ist.sieroter Milan., 56: 583–588.Google Scholar
  7. Bolton, C. H., Hampton, J. R., and Phillipson, O. T, 1968, Platelet behaviour and plasma phospholipids in MS., Lancet., 1: 99–104.CrossRefGoogle Scholar
  8. Bornstein, M. B., and Appel, S. H., 1965, Tissue culture studies of demyelination, Ann.NY Acad.Sci., 122: 280–286.CrossRefGoogle Scholar
  9. Brante, G., 1949, Studies on lipids in the nervous system with special reference to qualitative chemical determination and topical distribution, Acta Physiol.Scand., (Suppl. 63), Stockholm, 18: 1–20.Google Scholar
  10. Brock, J., and Field, E. J., 1975, Unsaturated Fatty Acids and Transplantation, Lancet., 1: 1382–1383.CrossRefGoogle Scholar
  11. Burr, G. O., and Burr, M. M., 1929, A new deficiency disease produced by the rigid exclusion of fat from diet, J.Biol.Chem., 82: 345–367.Google Scholar
  12. Burr, G. O., and Burr, M. M., 1930, On the nature and role of the fatty acids essential in nutrition, J.Biol.Chem., 86: 587–621.Google Scholar
  13. Castaigne, P., Lhermitte, F., Escourolle, R., Huan, J. J., Gray, F., and Lyon-Caen, O., 1981, Les scleroses en plaques asymptomatiques, Rev.Neurol.(Paris), 1937: 729–739.Google Scholar
  14. Charcot, J-M., 1872-1873, Lecons sur les maladies du systeme nerveux. Bournville, ed., Delahaye, Paris, 187–190.Google Scholar
  15. Charcot, J-M., 1886, Lecons sur les maladies du systeme nerveux, in: “Oeuvres completes de J-M Charcot”, Tome 1, Bournville, ed., Paris, 158–163.Google Scholar
  16. Charcot, J-M., 1892, Lecons du mardi à la Salpêtrifère, Vol. 1, Bataille, Paris, 392.Google Scholar
  17. Curtius, F. C., 1933, “Multiple Sklerose und Erbanlage”, Georh Thieme Verlag, Leipzig, 215.Google Scholar
  18. Dawson, J. W., 1916, The jistology of disseminated sclerosis, Trans.Roy.Soc.Edin., 50: 517–740.Google Scholar
  19. Dawson, R. M. C., and Gould, R. M., 1976, Renewal of phospholipids in the myelin sheath, Adv.Exp.Med.Biol., 72: 95–113.CrossRefGoogle Scholar
  20. Dean, G., Savettieri, G., Tairi, G., Morreale, S., and Karhausen, L., 1981, The prevalence of multiple sclerosis in Sicily, II Agrigento City, J.Epidemiol.Commun.Health., 35: 118–122.CrossRefGoogle Scholar
  21. DeJong, R. N., 1970, Multiple Sclerosis, History definition and general consideration, in: “Handbook of Clinical Neurology”, P.J. Vinken and G.W. Bruyn, eds., North Holland Publishing Co., Amsterdam and New York, 9: 45–63.Google Scholar
  22. Eichorst, H., 1896, Ueber infantile und hereditare multiple Sklerose, Archiv f.Pathol.Anat., 146: 173–192.Google Scholar
  23. Falconer, D. S., 1965, The inheritance of liability to certain diseases, estimated from the incidence among relatives, Ann.Hum.Genet.Lond., 29; 51–76.CrossRefGoogle Scholar
  24. Ferraro, A., and Davidoff, L. M., 1928, The reaction of the oligodendroglia to injury of the human brain, Arch.Path., 6: 1030–1063.Google Scholar
  25. Field, E. J., 1957, Histogenesis of compound granular corpuscles in the mouse brain after trauma and a note on the influence of cortisone, J.Neuropath.Exp.Neurol., 16: 48–56.CrossRefGoogle Scholar
  26. Field, E. J., 1967, The significance of astroglial hypertrophy in scrapie, kuru, multiple sclerosis and old age, together with a note on the possible nature of the scrapie agent, Dtsch Z. Nervenheilk., 192: 265–274.Google Scholar
  27. Field, E. J., 1980, “Multiple Sclerosis in Childhood: Treatment and Prophylaxis”, C.C. Thomas, Springfield, Illinois.Google Scholar
  28. Field, E. J., 1983, E-UFA Test, in: “Cell Separation Methods and Selected Application”, Vol. 2, T.G. Pretlow II and T.P. Pretlow, eds., Academic Press, New York and London, 251–271.Google Scholar
  29. Field, E. J., and Joyce, G., 1977, Prostaglandin (PGE2) and human erythrocyte mobility: a specific test for multiple sclerosis? IRCS Med.Sci., 5: 158–159.Google Scholar
  30. Field, E. J., and Joyce, G., 1978, Effect of prolonged ingestion of gamma-linolenate by MS patients, Eur.Neurol., 17: 67–76.CrossRefGoogle Scholar
  31. Field, E. J., and Joyce, G., 1979, Multiple Sclerosis: what can and cannot be done, Brit.Med.J., 2: 1571–1572.CrossRefGoogle Scholar
  32. Field, E. J., and Joyce, G., 1980, Recent Methods of in vitro Diagnosis of Multiple Sclerosis, in: “Progress in Multiple Sclerosis Research”, H.J. Bauer, S. Poser and G. Ritter, eds., Springer-Verlag, Berlin and Heidelberg, 310–322.CrossRefGoogle Scholar
  33. Field, E.J., and Joyce, G., 1981, Simplified E-UFA test for Multiple Sclerosis (MS): Some sources of “false” results, J.Neurol., 226: 149–155.Google Scholar
  34. Field, E. J., and Joyce, G., 1982a, An Office Test for Multiple Sclerosis, IRCS Med.Sci., 10: 560–561.Google Scholar
  35. Field, E. J ., and Joyce, G., 1982b, A laboratory test to achieve assured ascertainment of MS; frequency in epidemiological studies and clinical trials, in: “Multiple Sclerosis East and West”, Y. Kuroiura and L.T. Kurland, eds., Kyushu University Press, Fukuoka, Japan, 265–272.Google Scholar
  36. Field, E. J., and Joyce, G., 1983, Multiple Sclerosis: Effect of gamma-linolenate administration upon membranes and the need for extended clinical trials of unsaturated fatty acids, Eur.Neurol., 22: 78–83.CrossRefGoogle Scholar
  37. Field, E. J., and Raine, C. S., 1966, Experimental allergic encephalomyelitis: an electron microscope study, Amer.J.Path., 49: 537–553.Google Scholar
  38. Field, E. J., and Shenton, B. K., 1975, Inhibitory effect of unsaturated fatty acids on lymphocyte–antigen interaction with special reference to Multiple Sclerosis, Acta Neurol.Scand., 52: 299–309.CrossRefGoogle Scholar
  39. Field, E. J., Miller, H., and Russell, D. S., 1962, Observations on glial inclusion bodies in a case of acute disseminated sclerosis, Brit.J.Clin.Path., 15: 278–284.CrossRefGoogle Scholar
  40. Field, E. J., Shenton, B. K., and Joyce, G., 1974, Specific laboratory testing for diagnosis of Multiple Sclerosis, Brit.Med.J., 1: 412–414.CrossRefGoogle Scholar
  41. Field, E. J., Joyce, G., and Smith, B. M., 1977, Erythrocyte-UFA (E-UFA) mobility test for Multiple Sclerosis: Implications for pathogenesis and handling of the disease, J.Neurol., 214: 113–127.CrossRefGoogle Scholar
  42. Fine, P. E. M., 1977, Analysis of family history data for evidence of non-Mendelian inheritance resulting from vertical transmission, J.Med.Genet., 14: 399–407.CrossRefGoogle Scholar
  43. Fine, P. E. M., 1978, Mitochondrial inheritance and disease, Lancet, 2: 659–662.CrossRefGoogle Scholar
  44. Fog, T., 1977, Clues from clinical features, in: “Multiple Sclerosis: A Critical Conspectus”, E.J. Field, ed., MTP Press Ltd, Lancaster, England, 13–33.Google Scholar
  45. Georgi, W., 1961, Multiple Sklerose, Pathologischanatomische Befunde multipler Sklerose bei klinisch nicht diagnostizierten Krankheiten, Schveiz.Med.Wochenschr., 91: 606–607.Google Scholar
  46. Ghatak, N. R., Hirano, A., Litjmaer, H., and Zimmerman, H. M., 1974, Asymptomatic demyelinated plaque, Arch.Neurz.(Chic)., 30: 484–486.CrossRefGoogle Scholar
  47. Gould, R. M., 1977, Incorporation of glycoproteins into peripheral nerve myelin, J.Cell Biol., 75: 306–338.CrossRefGoogle Scholar
  48. Gowers, W., 1902, A lecture on abiotrophy, Lancer, 1: 1003–1007.Google Scholar
  49. Gul, S., Smith, A. D., Thompson, R. H. S., Payling Wright, H., and Zilkha, K. J., 1970, The fatty acid composition of phospholipids from platelets and erythrocytes in Multiple Sclerosis, J.Neurol.Neurosurg. Psychiat., 33: 506–510.CrossRefGoogle Scholar
  50. Hassin, G. B., 1922, Studies in the pathogenesis of Multiple Sclerosis, Arch.Neurol.Psychiat., 7: 589–607.CrossRefGoogle Scholar
  51. Hassin, G. B., 1937, Pathologic features of multiple sclerosis and allied conditions, Arch.Neurol.Psychiat., 38: 713–724.CrossRefGoogle Scholar
  52. Himsworth, H. P., 1949, The syndrome of diabetes mellitus and its causes, Lancet, 1: 465–473.CrossRefGoogle Scholar
  53. Holman, R. T., 1978, How essential are essential fatty acids? J.Amer.Oil Chemists Soc., 55: 774A–781A.CrossRefGoogle Scholar
  54. Homa, S. T., Belin, J., Smith, A. D., Monro, J. A., and Zilkha, K. J., 1980, Levels of linolenate and arachidonate in red blood cells of healthy individuals and patients with multiple sclerosis, J.Neurol.Neurosurg.Psychiat., 43: 106–110.CrossRefGoogle Scholar
  55. Homa, S. T., Conroy, D. M., Belin, J., Smith, A. D., and Zilkha, K. J., 1981, Fatty acid patterns of red blood cell phospholipids in patients with multiple sclerosis, Lancet, 2: 474.CrossRefGoogle Scholar
  56. Horrocks, L. A., 1973, Compounds and metabolism of myelin phosphoglycerides during maturation and ageing, Prog.Brain Res., 40: 383–387.CrossRefGoogle Scholar
  57. Hughes, D., and Field, E. J., 1967, Myelotoxicity of serum and spinal fluid in MS: a critical assessment, Clin.Exp.Immunol., 2: 295–309.Google Scholar
  58. James, P. B., 1982, Evidence for subacute fat embolism as the cause of Multiple Sclerosis, Lancet, 1: 380–386.CrossRefGoogle Scholar
  59. James, P. B., 1983, Oxygen for Multiple Sclerosis, Lancet, 2: 632.Google Scholar
  60. Jenssen, H. L., Meyer-Rienecker, H. J., Kohler, H., and Gunther, J. K., 1976, The Linoleic Acid Depresseion (LAD) Test for Multiple Sclerosis using the Macrophage Electrophoretic Mobility ( MEM) Test, Acta Neurol.Scand., 53: 51–60.CrossRefGoogle Scholar
  61. Joyce, G., and Field, E. J., 1980, Further observations with the Erythrocyte-Unsaturated Fatty Acid Test. A contribution to the Genetics of Multiple Sclerosis, Eur.Neurol., 19: 266–272.CrossRefGoogle Scholar
  62. Jones, R., Capildeo, R., Rose, C. F., Forrester, J. A., Luckman, N. P., and Preece, A. W., 1981, A diagnostic test for multiple sclerosis using glutaraldehyde fixed erythrocytes and laser cytopherometry, in: “Cell Electrophoresis in Cancer and Other Clinical Research”, A.W. Preece and P. Ann Light, eds., Elsevier/North Holland Biomedical Press, Amsterdam, New York, Oxford, 189–195.Google Scholar
  63. Jungawala, F. B., and Dawson, R. M. C., 1971, The turnover of myelin phospholipids in the adult developing rat brain, Biochem.J., 123: 683–693.Google Scholar
  64. Lampert, P., and Carpenter, S., 1965, Electron microscope studies on the vascular permeability and the mechanism of demyelination in experimental allergic encephalomyelitis, J.Neuropath.Exp. Neurol., 24: 11–24.Google Scholar
  65. Love, W. C., Cashell, A., Reynolds, M., and Callaghan, N., 1974, Linoleate and fatty acid patterns of serum lipids in multiple sclerosis and other disease, Brit.Med.J., 2: 18–21.CrossRefGoogle Scholar
  66. Lumsden, C. E., 1970, The neuropathology of MS, in: “Handbook of Clinical Neurology”, P.J. Vinken and G.W. Bruyn, eds., North Holland Publishing Co., Amsterdam and New York, 9: 217–309.Google Scholar
  67. Mackay, R. P., and Hirano, A., 1967, Forms of benign Multiple Sclerosis, Arch.Neurol.(Chic.), 17: 588–600.CrossRefGoogle Scholar
  68. Mackenzie, A., and Wilson, A. M., 1966, Accumulation of fat in the brains of mice affected with scrapie, Res.Vet.Sci., 7: 45–54.Google Scholar
  69. Matthews, W. B., 1979, Neurosarcoidosis, in: “Handbook of Clinical Neurology”, P.J. Vinken, G.W. Bruyn and H. Klawans, eds., North Holland Publishing Co., Amsterdam and New York, 38, part 1:521–542.Google Scholar
  70. McHugh, M. I., Wilkinson, R., Elliott, R. W., Field, E. F., Dewar, P., Hall, P. R., Taylor, R. M. R., and Uldall, P. R., 1977, Immunosuppression with polyunsaturated fatty acids in renal transplantation, Transplantation, 24: 263–267.CrossRefGoogle Scholar
  71. Mertin, J., 1974, Unsaturated fatty acids and renal transplantation, Lancet, 2: 717.CrossRefGoogle Scholar
  72. Mertin, J., Field, E. J., and Caspary, E. A., 1973, Unsaturated fatty acids in multiple sclerosis, Brit.Med.J., 2: 777.CrossRefGoogle Scholar
  73. Millar, J. H. D., Zilkja, K. J., Langman, M. J. S., Payling Wright, H., SMith, A. D., Belin, J., and Thompson, R. H. S., 1973, Double blind trial of linoleate supplementation of the diet in multiple sclerosis, Brit.Med.J., 1: 756–768.CrossRefGoogle Scholar
  74. Morariu, M., and Klutzow, W. F., 1976, Subclinical Multiple Sclerosis, J.Neurol., 213: 71–76.CrossRefGoogle Scholar
  75. Moya, G., 1962, Sclerose en plaques familiales. Etude critique de leur signification, Acta Psychiat.Belg., 62: 40–94.Google Scholar
  76. Müller, E., 1904, Die multiple Sklerose des Gehirns und Riickenmarks, Verlag von G. Fisher, Jena.Google Scholar
  77. Myrianthopoulos, N. C., 1970, Genetic aspects of multiple sclerosis, in: “Handbook of Neurology”, P.J. Vinken and G.W. Bruyn, eds., North Holland Publishing Co., Amsterdam and New York, 9: 85–106.Google Scholar
  78. Norton, W. T., and Podulso, S. E., 1973, Myelination in rat brain. Changes in Myelin composition during brain maturation, J.Neurochem., 21: 759–762.CrossRefGoogle Scholar
  79. Peters, G., 1958, Multiple Sklerose, in: “Handbuch der Spezellen Pathologischen Anatomie und Histologic”, P. Lubarsh, F. Henke, and R. Rossle, eds., Springer-Verlag, Berlin, Gottingen and Heidelberg, 13 part 11: 525–602.Google Scholar
  80. Rindfleisch, E. E., 1863, Histologisches Detail zu der graven Degeneration von Gehirn und Ruckenmark, Virchows Arch., 26: 474–483.CrossRefGoogle Scholar
  81. Ring, J., Seifert, J., Mertin, J., and Brendel, W., 1974, Prolongation of skin allografts in rats by treatment with linoleic acid, Lancet, 2: 1331.CrossRefGoogle Scholar
  82. Rossolimo, G., 1897, Zur Frage uber die multiple Sklerose und Gliose, Deutsch.Zeitschr.f.Nervenheilk., 11: 89–121.Google Scholar
  83. Scherer, H. J., 1938, La “Glioblastomatose en plaques” sur les limites anatomiques de la gliomatose et des processus scl£rotique progressifs (sclerose en plaques, sclerose diffuse de Schilder, sclerose concentrique), J.Beige Neurol., 38: 1–17.Google Scholar
  84. Seaman, G. V. F., Swank, R. L., and Zukoski, C. F.iv, 1979b, Red-Cell membrane differences in multiple sclerosis are acquired from plasma, Lancet, 1: 1139.CrossRefGoogle Scholar
  85. Siemerling, E., and Raecke, J., 1911, Zur pathologischen Anatomie und Pathogenese der multiplen Sklerose, Arch.f.Psychiat.u. Nervenkr., 43: 824–840.Google Scholar
  86. Siemerling, E., and Raecke, J., 1914, Beitrag zur Klinik und Pathologie der multiplen Sklerose mit besonderer Berücksichtigung ihrer Pathogenese, Arch.f.Psychiat.u. Nervenkr., 53: 385–564.Google Scholar
  87. Sinclair, H. M., 1956, Deficiency of essential fatty acids and atherosclerosis, etcetera, Lancet, 1: 381–383.Google Scholar
  88. Sinclair, H. M., 1982, Icosapentaenoic acid and ischaemic heart disease, Lancet, 2: 383.Google Scholar
  89. Stengel, D., and Hanoune, J., 1981, The catalytic unit of ram sperm adenylate cyclase can be activated through the guanine nucleo tide regulatory component and prostaglandin receptors of human erythrocyte, J.Biol.Chem., 256: 5394–5398.Google Scholar
  90. Strahuber, A., 1903, Ueber Degenerations–und proliferationsvorgange bei multipler Sklerose des Nervensystems, Zieglers Beitr.zu Path.Anat., 33: 409–480.Google Scholar
  91. Swank, R. L., 1950, Multiple Sclerosis: A correlation of its incidence with dietary fat, Am.J.Med.Sci., 220: 421–430.Google Scholar
  92. Swank, R. L., 1970, Multiple Sclerosis: Twenty years on low fat diet, Arch.Neurol., 23: 460–474.Google Scholar
  93. Tamblyn, C. H., Swank, R. L., Seaman, G. V. F., and Zukoski, C. F.iv, 1980, Red cell electrophoretic mobility test for early diagnosis of multiple sclerosis, Neurol.Res., 2: 69–83.Google Scholar
  94. Thompson, R. H. S., 1966, A biochemical approach to the problem of multiple sclerosis, Proc.Roy.Soc.Med., 59: 269–276.Google Scholar
  95. Thompson, R. H. S., 1973, Fatty acid metabolism in multiple sclerosis, Biochem.Soc.Symp., 35: 103–111.Google Scholar
  96. Tingley, A. H., 1956, Human brain lipids at various ages in relation to myelination, J.Ment.Sci.London, 102: 851–855.Google Scholar
  97. Turnell, R. W., Clark, L. H., and Burton, A. F., 1973, Studies on the mechanism of corticosteroid–induced lymphocytolysis, Cancer Res., 33: 203–212.Google Scholar
  98. Vost, A., Wolochow, A., and Howell, D. A., 1964, Incidence of infarcts of the brain in heart disease, J.Path.Bact., 88: 463–470.CrossRefGoogle Scholar
  99. Waksman, B. H., 1959, Experimental Allergic Encephalomyelitis and the “Auto Allergic” diseases, Int.Arch.Allerg. and Appl.Immunol., Suppl. 14: 1–87.Google Scholar
  100. Yakovlev, P. I., and Lecours, A. R., 1967, The myelogenetic cycles of regional maturation in the brain, in: “Regional Development of the Brain”, A. Minkowski, ed., Blackwell Scientific Publishers, Oxford and Edinburgh, 3–70.Google Scholar
  101. Zollinger, H. U., 1941, Groszellig-granulomatose Lymphangitis cerebri ( Morbus Boeck) unter dem Bilde einer multiplen Sklerose verlaufend, Virchows Arch., 307: 597–615.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • E. J. Field
    • 1
  1. 1.Crossley House Neurological Research CentreNewcastle upon TyneEngland

Personalised recommendations